Odyssey Therapeutics Acquisition | Healthcare Deal in MA

Odyssey Therapeutics has completed the pricing of an upsized initial public offering, a healthcare services other business in Massachusetts, for $304 million. Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing targeted medicines for autoimmune and inflammatory diseases, with common stock expected to begin trading on Nasdaq Capital Market under ticker ODTX in May 2026. The company plans to sell 15,500,000 shares at $18.00 per share, with an underwriters’ 30-day option for up to 2,325,000 additional shares, plus a concurrent private placement of 1,388,889 shares to an affiliate of TPG Life Sciences Innovations. The healthcare M&A context is limited because this is an other acquisition-style capital raise rather than an MA acquisitions deal, with J.P. Morgan, TD Cowen, and Cantor as joint book-running managers and an expected close on or about May 11, 2026.